Legand Biotech Corp. (LEGN) R&D Day Reinforces Expectations for a Seamless Citacel Launch - Jefferies
Tweet Send to a Friend
Jefferies analyst Kelly Shi reiterated a Buy rating and $56.00 price target on Legand Biotech Corp. (NASDAQ: LEGN) after attending ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
